Hôpital gynéco-obstétrique et pédiatrique de Yaoundé (HGOPY)
Yaoundé, Cameroon
NCT Number: NCT03733678
Cameroon exhibits a high and non-decreasing level of maternal mortality (roughly 600 per 100,000 live births), partially related to its relatively high total fertility rate (roughly 4.6). Survey evidence furthermore suggests that a significant fraction of these pregnancies is unwanted or considered mistimed by the mother, especially among females aged 15-19. Despite this, the rate of utilization of family planning (FP) is low: e.g. only 48% of sexually active unmarried women use any form of (modern) contraception, or MC, and even then, it is primarily condoms. The use of LARCs (long-acting reversible contraceptives, i.e. the IUD and implant) is less than 1% according to the most recent Demographic Health Survey.
The study investigators propose to use an integrated behavioral science approach to increase the take-up of both SARCs (short-acting reversible contraceptives, i.e. the pill and injectable) and especially LARCs among reproductive-age females in Cameroon, including adolescents who may be unmarried and/or nulliparous. In addition to decreasing maternal mortality and undesired pregnancies, indirect effects for the community will include: increased welfare from reduced side effects that arise due to current one-size-fits-all FP counseling; healthier children due to improved birth spacing; and increased human capital formation both for children and for young (often school-aged) potential mothers.
The study investigators propose to conduct the study at HGOPY for a duration of 12 months. The study investigators will provide tablets to each of five nurses that conduct FP counseling to participants at the hospital. The tablets contain a counseling "app" (or decision-support tool or a job-aid) that was jointly developed by professionals from HGOPY, the World Bank, and the Ministry of Health. The study investigators propose an individually-randomized experiment, where the participants will be offered randomly varying discounts for the modern contraceptive methods they wish to adopt. The study investigators also propose to experiment with certain aspects of the "app" to improve its effectiveness - both for the participant and for the nurse. More details on the experimental design are provided below.
Looking for future studies?
Notify Me10 year–49 year
Female
Interventional
Not applicable
Yaoundé, Cameroon
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
SARCs are offered free to the client
LARCs are offered at lower prices to the client
Top ranked methods are presented to the client sequentially or simultaneously
Time frame: 1-day
using data from the counseling sessions
Time frame: 1-day
using data from the counseling sessions
Time frame: 2-weeks
Self-reported indicator variable using follow-up surveys two weeks after counseling session
Time frame: 2-weeks
Self-reported indicator variable using follow-up surveys two weeks after counseling session
Time frame: 2-weeks
Self-reported indicator variable using follow-up surveys two weeks after counseling session
Time frame: 2-week and 16-week measurements
using 2-week and 16-week follow-up surveys
Time frame: 2-week, 16-week, and 52-week measurements
using 2-week, 16-week, and 52-week follow-up surveys
Time frame: 16-week and 52-week measurements
using 16-week and 52-week follow-up surveys
World Bank
Other
A Sequential and Adaptive Experiment to Increase the Uptake of Long-acting Reversible Contraceptives in Cameroon
Acronym: HGOPY
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04423068
Behavior, Contraception
Kansas City, Missouri, United States
View Trial DetailsNCT03979950
Behavior, Contraception
La Jolla, California, United States
View Trial DetailsNCT03571932
Behavior, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
View Trial DetailsNCT03404284
Behavior, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
View Trial Details